Introduction {#s0005}
============

While considerable evidence supports the role of oxidative stress in the development and progression of chronic diseases such as heart failure (HF) [@bib1; @bib2; @bib3; @bib4], clinical trials with natural antioxidant interventions conducted in the last two decades have yielded controversial results [@bib5; @bib6; @bib7; @bib8; @bib9]. However, until 2000, the few clinical studies that documented circulating biomarkers of oxidative stress predominantly measured the plasma level of malondialdehyde (MDA) using the highly criticized thiobarbituric acid-reactive substances (TBARS) method without chromatographic separation [@bib3; @bib10; @bib11; @bib12; @bib13]. More recently, urinary and plasma isoprostanes, which arise from the peroxidation of the *n*-*6* polyunsaturated fatty acid (PUFA) arachidonic acid (AA), have been advocated for the in vivo assessment of oxidative stress status for human studies [@bib14; @bib15; @bib16]. However, it appears unlikely that the measurement of a single biomarker will provide a comprehensive picture of the various oxidative stress-related events that may contribute to progression of cardiovascular diseases [@bib17].

Another peroxidation product of the *n*-*6* PUFAs AA and linoleic acid (LA) that has generated considerable research interest for its potential as a biomarker of oxidative stress is 4-hydroxynonenal (4HNE) [@bib18]. This aldehyde readily binds covalently to nucleophilic residues of proteins, peptides, phospholipids, and nucleic acids and thereby exhibits cytotoxic effects. 4HNE can also modulate signaling pathways involved in cell proliferation, fibrosis, apoptosis and inflammation, which are all hallmarks of cardiovascular diseases, especially HF [@bib19; @bib20; @bib21]. Interestingly, Nakamura et al. showed that the myocardial levels of protein-bound 4HNE were decreased after treatment with carvedilol in patients with HF [@bib22], and were also correlated with left ventricular dilatation and systolic dysfunction in patients with hypertrophic cardiomyopathy [@bib23]. Recently, we developed and validated a method using gas chromatography-mass spectrometry to quantify, with precision, blood levels of total protein-bound 4HNE thioether adducts (4HNE-P) [@bib24]. Using this method, we reported a higher accumulation of blood 4HNE-P in spontaneously hypertensive rats than in normal rats, which correlated positively with left ventricular diastolic dysfunction [@bib24; @bib25], and in hypercholesterolemic rabbits [@bib26]. These findings support a role for this biomarker in the pathophysiological events linked to heart disease progression, although it has not yet been documented in humans.

Measurements of oxidative stress in cohorts of patients with HF have, however, yielded controversial results, with some studies [@bib13; @bib27; @bib28] reporting an increase in these biomarkers. This discrepancy has been attributed in part to current drug therapies [@bib29] that include β-blockers [@bib22; @bib28; @bib30], renin-angiotensin system (RAS) inhibitor, and statins [@bib31; @bib32], which exert indirect antioxidant effects through regulation of free radical-producing processes or of antioxidant defenses. However, since commonly measured biomarkers of oxidative stress are predominantly lipid peroxidation products, one other factor that may contribute to this discrepancy is the circulating level of PUFAs, which are the precursors of these biomarkers and are affected by disease [@bib33] and/or by pharmacological treatment such as statins [@bib34]. In their recent review, Halliwell and Lee [@bib35] recognized that this issue should be further explored.

Therefore, in this study we tested the hypothesis that circulating levels of the lipid peroxidation product 4-hydroxynonenal bound to proteins (4HNE-P) are strongly associated with those of its potential precursors. Hence, we documented circulating levels of (i) biomarkers of oxidative stress, including 4HNE-P but also the commonly assessed malondialdehyde, as well as (ii) total fatty acids, which include all classes of fatty acids and reflect both free and bound fatty acids, either to albumin or esterified to cholesterol or as triglycerides and phospholipids in lipoproteins, in a population of 61 symptomatic ambulatory HF patients receiving evidence-based therapies and 71 control subjects.

Patients and methods {#s0010}
====================

Study population and design {#s0015}
---------------------------

This study involved a total of 132 subjects. A group of 61 symptomatic patients followed at the Heart Failure Clinic of the Montreal Heart Institute (HFC-MHI) who were older than 45 years and had a left ventricular ejection fraction ≤40%, as determined by echocardiography, was studied. The HFC-MHI is a multidisciplinary specialized outpatient disease management program. Symptomatic HF patients are referred to the clinic by a MHI cardiologist after an emergency department visit or a hospital admission for documented HF. Thus, this clinic is restricted to patients at high risk of decompensation, needing a close medical follow-up [@bib36]. For the purpose of this analysis, patients with recent (\<3 months) cardiac surgery were excluded. We also studied 71 control subjects who were older than 45 years and free of significant cardiovascular disease or risk factors such as diabetes mellitus, untreated dyslipidemia or hypertension, severe obesity (Body mass index ≥32 kg/m^2^) or cigarette smoking (≥25/day). Complete medical assessment, including history and physical examination, was performed and a 20-ml blood sample was drawn from an antecubital vein after overnight fast. Blood and plasma samples were collected in EDTA tube and immediately frozen in liquid nitrogen and stored at −80 °C until assayed. The investigation conformed to the principles outlined in the Declaration of Helsinki. The study protocol was approved by the MHI research ethics committee and all subjects gave written informed consent.

Biochemical determinations and calculations {#s0020}
-------------------------------------------

The following assays on plasma samples were performed according to the manufacturer\'s instructions: glucose, creatinine, blood urea, HDL-cholesterol and triglycerides were determined by spectrophotometric methods, using respective reagent Flex on a multianalyzer Dimension RxL Max (Dade Behring Diagnostics, Marburg, Germany), N-terminal proB-type natriuretic peptide (NT-proBNP) and troponin T were assessed by electrochemiluminescence immunoassay on a Elecsys 2010 analyzer using Roche assay kits (Roche Diagnostic, Mannheim, Germany), and C-reactive protein (CRP) was quantified using the Dade Behring N High Sensitivity assay (Dade Behring Diagnostics, Marburg, Germany) on the BN ProSpec Nephelometer. Insulin was quantified by a double-antibody radioimmunoassay (Bi-Ins-IRMA kit, CIS Bio International, Gif-sur-Yvette, France). ELISA kits were used to assess levels of Tumor Necrosis Factor-alpha (TNF-α) (R&D Systems, Minneapolis, USA) and myeloperoxidase (MPO) (Oxis International Inc., Foster City, USA). Levels of reduced (GSH) and oxidized (GSSG) glutathione were determined in 200 µl of whole blood by capillary electrophoresis according to Serru et al. [@bib37]. The amount of free MDA formed during the TBARS reaction was determined by HPLC, and the plasma fatty acid composition was assessed as previously described with some minor modifications [@bib38; @bib39]. The estimated glomerular filtration rate (eGFR) and the homeostatic model assessment of insulin resistance (HOMA-IR) were calculated by the Cockcroft and Gault [@bib40] and Matthews [@bib41] formulas, respectively. The cholesterol ratio was calculated from the total-cholesterol value divided by the HDL-cholesterol value.

Statistical analysis {#s0025}
--------------------

Patient characteristics are expressed as mean±SD, median \[min−max\], or frequencies and percentages when appropriate. Because of significant differences in age and gender between the control and HF patients, comparisons between these two groups of subjects for clinical and biochemical characteristics were conducted using an analysis of covariance (ANCOVA) adjusting for age and sex as covariates. For parameters exhibiting a severely skewed distribution, a logarithmic transformation was used. To test for NYHA classes and type 2 diabetes among the HF group, categorical variables were analyzed using Pearson chi-square tests and continuous variables with *t*-tests or Mann--Whitney--Wilcoxon tests (according to the distribution of the variable). Supplementary analyses were conducted for (i) primary outcomes measures, namely the oxidative stress marker 4HNE-P and its potential precursors the *n*-*6* PUFA LA, as well as for the commonly assessed oxidative stress marker MDA. For LA, covariance analysis was conducted for further adjusting values to plasma levels of the various cholesterol classes (total, LDL- and HDL-cholesterol) as covariates, in addition to age and gender. For 4HNE-P, Pearson correlation analyses were conducted to test its association with its potential precursors. We assessed also risk factors and parameters associated with its circulating levels using multiple linear regression analysis. This analysis was performed (i) in the entire population and subsequently (ii) in HF patients only using the following risk factors and parameters, which were selected for their high clinical and biochemical relevance: (i) group, age, body mass index, sex, log NT-proBNP, malondialdehyde (MDA), reduced-to-oxidized glutathione ratio, myeloperoxidase, lymphocytes, tumor necrosis factor-α, C-reactive protein, HDL-cholesterol, LDL-cholesterol, triglycerides, insulin, glucose, uric acid, estimated glomerular filtration rate, total bilirubin, alkaline phosphatase, linoleic acid and arachidonic acid, and (ii) all parameters listed in (i) except group, plus systolic pressure, NYHA class, left ventricular ejection fraction, etiology, non-insulin dependent diabetes mellitus, hypertension, myocardial infarction, medication (β-blocker, RAS inhibitor, calcium channel inhibitor, chronic nitrate, acute nitrate, amiodarone, digoxin, warfarin, salicylates, diuretics, hypolipidemic agents, hypoglycemic agents, allopurinol). For MDA, we have also conducted a multiple linear regression analysis in HF patients only using the same risk factors and parameters listed above for 4HNE-P, except that MDA was replaced with 4HNE-P. All these parameters were entered into a stepwise selection procedure with a 0.1 significance level for staying in the model. Parameters with a *P*-value between 0.05 and 0.1 were kept in the model to indicate potential trends. A *P*-value \<0.05 was considered statistically significant. Statistical analyses were performed using SAS version 9.1 or higher (Cary, NC, USA).

Results {#s0030}
=======

Clinical and biochemical characteristics of HF patients and controls, including medications used, are summarized in [Tables 1 and 2](#t0005 t0010){ref-type="table"}; these tables include parameters routinely assessed in clinical laboratories. Circulating levels of lipid peroxidation markers and of their potential *n*-*6* PUFA precursors, as well as other fatty acids can be found in [Tables 3 and 4](#t0015 t0020){ref-type="table"}, respectively. Because the HF patient cohort was slightly older and had a greater proportion of men than controls, all tables report only statistical differences which remained significant after adjustment for age- and gender-differences.

Clinical and biochemical characteristics of the study population {#s0035}
----------------------------------------------------------------

Our population of HF patients had a markedly depressed left ventricular ejection fraction with a mean of 26.3±7.1% and moderate to severe functional impairment, being mostly in New York Heart Association (NYHA) classes II (54%) and III (44%). These patients were mostly of ischemic etiology (66%) and the vast majority of them presented 2 or more comorbidities, such as type 2 diabetes (48%) and hypertension (49%). Finally, as per guidelines recommendation, HF patients received multiple medications compared to controls (7.4±2.0 vs. 0.8±1.2 medications/subject, *P*\<0.0001), which included diuretics (97%), RAS inhibitors (85%), β-blockers (79%), lipid-lowering agents (75%), warfarin (48%) and salicylates (65%).

With respect to circulating parameters routinely assessed in the clinical laboratory, as expected, HF patients exhibited markedly increased plasma levels of NT-ProBNP, uric acid, urea and creatine; some degree of renal dysfunction was evidenced by a lower eGFR. While 16% of them had an elevated plasma troponin T level (≥0.03 μg/L), their plasma levels of inflammation markers namely TNF-α (50%), CRP (71%) and MPO (41%), were also significantly higher.

At the metabolic levels, HF patients displayed markedly lower levels of HDL-cholesterol (38%) and LDL-cholesterol (23%), but a greater \[total cholesterol\]/\[HDL-cholesterol\] ratio (21%), and higher levels of triglycerides (51%). They also showed significantly higher plasma levels of glucose (55%) and insulin (56%), as well as HOMA-IR scores (135%).

It is noteworthy that none of the reported parameters in [Tables 1 and 2](#t0005 t0010){ref-type="table"} were found to differ significantly between NYHA classes I--II vs. III of HF patients (data not shown) and only a few of them differed significantly between HF patients with or without type 2 diabetes (diastolic blood pressure: *p*\<0.01, glucose *p*\<0.0001 and HOMA-IR *p*\<0.03).

Circulating levels of lipid peroxidation markers and their potential fatty acid precursors {#s0040}
------------------------------------------------------------------------------------------

HF patients depicted significantly elevated levels of blood GSH-to-GSSG ratio (55%; [Table 3](#t0015){ref-type="table"}). This higher ratio was due to a significantly decreased blood level of GSSG (22%), while those of GSH and total glutathione were similar in both groups. Similarly, compared to controls, HF patients displayed similar circulating levels of MDA, a commonly assessed lipid peroxidation marker, as well 4HNE-P ([Table 3](#t0015){ref-type="table"}).

With regards to the plasma level of total fatty acids, which reflect both free and bound fatty acids, either to albumin or esterified to cholesterol or as triglycerides and phospholipids in lipoproteins, this did not differ between groups. However, concurring with literature data [@bib33], HF displayed a markedly altered fatty acid profile compared to controls ([Table 4](#t0020){ref-type="table"}), including decreased level of potential 4HNE-P precursors the *n*-*6* PUFA, specifically LA (by 15%) that represents \~75% of all *n*-*6* PUFA, while that of arachidonic acid was unchanged. There were also changes in the plasma levels of other fatty acid classes, namely a decrease in the level of *n*-*3* PUFAs, with an increased *n*-*6*/*n*-*3* PUFA ratio (11.7±3.4 vs. 9.1±3.0, *P*\<0.0001), while that of mono-unsaturated fatty acids (MUFA) was higher and saturated fatty acids remained unchanged. In the *n*-*3* series, the levels of both EPA and DHA were lower by almost 50%. It is noteworthy that, despite their lower levels of *n*-*6* and *n*-*3* PUFAs, HF patients do not depict essential fatty acid deficiency as a result of undernutrition or fat malabsorption, since the ratio (20:3n-9/20:4n-6) and (C16:1n-7/18:2n-6) remained within the normal range [@bib42].

Circulating levels of 4HNE-P, but not MDA, are associated to that of its potential PUFA precursors {#s0045}
--------------------------------------------------------------------------------------------------

Additional statistical analyses, both univariate correlation Pearson analysis as well as multivariate regression analysis ([Table 5](#t0025){ref-type="table"}), which included both age and gender as variables, were conducted in the entire population and revealed a strong association between circulating 4HNE-P and its potential precursor LA. In fact, using multiple regression analysis, LA was found to be the only parameter that was positively associated with 4HNE-P in the entire population (β-coefficient 0.0139, *P*=0.0183).

Results from the univariate analysis conducted in the two groups of subjects separately revealed, however, that only the HF group showed a significant association between 4HNE-P and LA ([Table 5](#t0025){ref-type="table"}). The relationship between 4HNE-P and LA for the two groups is depicted in [Fig. 1](#f0005){ref-type="fig"}.

When multiple regression analyses were conducted in the HF group only, LA remained strongly associated with 4HNE-P ([Table 6](#t0030){ref-type="table"}). The multiple regression analysis suggested, however, additional factors that could explain variations in blood levels of 4HNE-P in HF patients (*R*^2^=0.5692) and the strongest association was found for HDL-cholesterol (*P*\<0.0002). Interestingly, 4HNE-P in HF patients was found to be also associated positively with disease-related parameters such as the NYHA class. The aforementioned associations appear specific to 4HNE-P, since MDA, which is another product of peroxidation of *n*-*6* PUFA, was not found to be significantly associated with either LA or arachidonic acid in an univariate Pearson correlation analysis (data not shown) nor in multiple regression analysis conducted in the entire population neither in HF patients using MDA as the dependent variable ([Table 6](#t0030){ref-type="table"}). In fact, MDA showed significant positive associations with plasma glucose only, as well as MPO and hypertension.

Further to results of our multiple regression analysis, supplemental analyses were conducted in the entire population to explore the relationship between LA and the specific cholesterol fractions, and more specifically HDL-cholesterol. Using Pearson correlation tests, we found a strong positive association between LA and each of the cholesterol fraction (*P*\<0.0001): total cholesterol (*R*=0.771, *P*\<0.0001)\>LDL-cholesterol (*R*=0.674, *P*\<0.0001)\>HDL-cholesterol (*R*=0.276, *P*=0.0013) ([Fig. 2](#f0010){ref-type="fig"}A). In addition, covariance analysis was conducted using age, gender and the plasma levels of the various cholesterol classes (total, LDL- and HDL-cholesterol) as covariates. After adjustment, the difference between HF patients and controls was no longer significantly different for LA (3895±97 vs. 3998±90 μM; *p*=0.40; [Fig. 2](#f0010){ref-type="fig"}B), suggesting that the difference in plasma level of LA between HF patients and controls is explained by that of cholesterol, total, HDL- and LDL-cholesterol. The relationship between 4HNE-P and HDL-cholesterol in HF patients and control subjects is depicted in [Fig. 3](#f0015){ref-type="fig"}: HNE-P levels are expressed either as absolute values ([Fig. 3](#f0015){ref-type="fig"}A), and as a molar ratio relative to HDL cholesterol, as an index of the content of 4HNE-P per unit of HDL-cholesterol molecule ([Fig. 3](#f0015){ref-type="fig"}B). Collectively, these results suggest that the HNE-P level expressed per unit of HDL-cholesterol increases as the plasma level of HDL-cholesterol decreases in the HF group.

Discussion {#s0050}
==========

In support of our initial working hypothesis, this study documents a significant strong association between circulating levels of 4HNE-P and its potential precursors, particularly the *n*-*6* PUFA LA and HDL-cholesterol. Given that the levels of these precursors are reduced significantly in HF patients compared to controls, this raises an important question about data interpretation of measurements of absolute values for plasma levels of 4HNE-P, and thereby emphasizes the importance of measuring changes in the levels of 4HNE-P with its potential precursors.

In fact, our results highlight significant positive associations between circulating levels of 4HNE-P and LA, a *n*-*6* PUFA, using univariate correlation and multiple regression analyses in the entire population. However, multiple regression analysis conducted in the HF group only revealed a stronger association with HDL-cholesterol than LA. Concurring with the notion that lipoproteins are the predominant PUFA carrier in plasma, plasma levels of LA were strongly correlated with those of HDL-cholesterol, and were no longer significantly different between the control and HF groups, when adjusted for the levels of total cholesterol, HDL- and LDL-cholesterol. Hence, on this basis, supplemental analyses were focused on the relationship between 4HNE-P and HDL-cholesterol.

Interestingly, these supplementary analyses demonstrate that the level of 4HNE-P, expressed relative to that of HDL-cholesterol, increases as the level of HDL-cholesterol decreases in the HF population. This may appear surprising given that HDL-cholesterol has been shown to exert a protective role against cardiovascular disease through multiple mechanisms [@bib43; @bib44]. However, a number of studies have shown that HDL, and not LDL, particles may well be the circulating lipoprotein that carries the greatest oxidized lipid load, and emphasized the consequences of oxidative damage to proteins comprised in HDL particles, which would make them dysfunctional and thereby contribute to disease outcome [@bib45; @bib46; @bib47; @bib48; @bib49; @bib50]. Consistent with this notion, Woodward et al. recently reported a strong positive correlation between plasma levels of the lipid peroxidation product F~2~-isoprostanes and HDL-cholesterol in a cohort of coronary patients and control subjects, although levels of F~2~-isoprostanes were not different between groups [@bib51]. Our finding of a positive association between HDL-cholesterol and circulating levels of total protein-bound 4HNE in HF patients in this study raise the possibility that this specific lipid peroxidation product may contribute to protein modification in HDL particles.

Beyond HDL-cholesterol, our multiple regression analysis revealed that circulating levels of 4HNE-P were also negatively associated with the GSH-to-GSSG ratio [@bib52; @bib53], which was elevated in HF patients suggesting an adaptive up-regulation of enzymes involved in glutathione synthesis and recycling in response to the increased oxidative stress in these patients. In support of this notion, abnormalities in GSH cycling were previously reported to be linked with increased lipid peroxidation in HF patients [@bib54]. It remains, however, unclear whether circulating sulfhydryl groups represent the first line of defense against reactive species that can initiate lipid peroxidation in blood of HF patients, which display high levels of MPO and leukocytes. Indeed, on the one hand, the relative abundance of circulating 4HNE-P levels has been shown to depend on their removal by phase II metabolic pathways such as gluthathione-S-transferases [@bib21]. On the other hand, Frei et al. [@bib55] showed that the formation of hydroperoxides from plasma cholesterol and phospholipid esters in the presence of activated leukocytes occurs following depletion of plasma ascorbate (known to scavenge the MPO oxidant hypochlorous acid) even though sulfhydryl groups are still present at high concentrations.

The participation of additional antioxidative mechanisms such as heme oygenase (HO) or paraoxonase in HDL-cholesterol particles [@bib56; @bib57], cannot be excluded. While we did not directly assess these mechanisms, indirect evidence supports a role for HO. Indeed, our multiple regression analysis in HF patients only revealed also a negative association between circulating levels of 4HNE-P and those of bilirubin. Interestingly, plasma bilirubin levels of HF patients were not significantly different from controls. Bilirubin, which is the end product of heme catabolism, has been shown to depict chain-breaking antioxidant properties [@bib58] and to inhibit peroxidation of lipids in lipoproteins [@bib59]. HO catalyzes heme oxidation and the induction of cardiac isoform (HO-1) under pathophysiological stresses has also been linked to inhibition of lipid peroxidation [@bib60; @bib61]. One potential source of non-protein-bound heme -- considered a particularly deleterious species -- is oxidation of hemoglobin released following erythrocyte lysis, which can be induced by lipid peroxidation end-products such as 4HNE [@bib62] and constitutes a well known mechanism that induces HO-1 [@bib63]. Interestingly, in this regard, is our finding of significantly lower hemoglobin levels in our HF patient cohort vs. controls.

Finally other factors identified by the multiple regression analyses include the NYHA class. Two small studies reported a link between NYHA classes and oxidative stress markers [@bib27; @bib64]. However, it should be noted that the characteristics of our HF patient population, which is typical for a HF clinic, did not provide adequate discrimination of the role of some clinically-relevant parameters in the multiple regression analysis. Additional studies are needed to substantiate this association using a larger HF and control cohort, which would be randomized for age and gender.

Interestingly, in contrast to 4HNE-P, plasma levels of MDA did not show any associations with LA or HDL-cholesterol or any other lipid parameters. In our study, MDA levels were not significantly elevated in HF patients, a finding that concurs with that of Tingberg et al. [@bib29], but contrasts with other studies [@bib13; @bib27; @bib65; @bib66]. It is noteworthy that while both 4HNE and MDA are lipid peroxidation by-products, MDA can also be generated by cyclooxygenases in thromboxane metabolism [@bib67] and from free radical attack on sialic acid and deoxyribose [@bib68]. Thus, these two biomarkers may reflect different pathogenic events linked to HF. This possibility is supported by the results of supplemental statistical analyses conducted in HF patients, which revealed that 4HNE-P and MDA were associated with different disease-related parameters and metabolites. Another factor that should also be considered is that we assessed free MDA levels in plasma, while 4HNE-P reflects 4HNE bound to all circulating proteins, which may be albumin or within lipoproteins, as it is suggested from by our correlation an multiple regression analyses. Nevertheless, the relationship depicted between 4HNE-P and its lipid precursors appears to be specific to 4HNE-P, and not MDA. Further studies are needed, however, to identify unambiguously circulating protein(s) that bind 4HNE, as well as factors that could explain the reduction in the circulating levels of lipoproteins as well as essential PUFAs, which include the *n*-*6* series, but also the *n*-*3* series. In this regard, other mass spectrometric methods combining enrichment strategies with targeted analysis such as neutral loss scanning should be used to enable detection and identification of 4HNE-modified proteins in complex biological matrices, including HDL particles [@bib18].

In conclusion, results from this study document a strong association between the lipid peroxidation product 4HNE-P, but not MDA, and its potential precursors the *n*-*6* PUFA LA and HDL-cholesterol, which is a major plasma PUFA carrier, in HF patients. This relationship suggests that in relative term, the level of 4HNE-P increases markedly as the level of HDL cholesterol decreases in these patients. Results from this study emphasize the importance of measuring the levels of these PUFA when assessing their lipid peroxidation by-products such as 4HNE-P. Based on our findings, it appears also warranted to test the possibility that 4HNE-P contributes to oxidative stress-induced HDL protein modification and dysfunction in HF patients.
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![Relationship between circulating levels of 4-hydroxynonenal bound to circulating thiol proteins (4HNE-P) and its precursor the *n*-*6* polyunsaturated fatty acid linoleic acid in control and heart failure (HF) subjects. The dotted lines show the linear regression lines with 95% confidence intervals for all subjects in the control (C) and HF group. Control: Linoleic acid=1.2×4HNE-P+3691, *P*=0.38 (NS), HF: Linoleic acid=6.5×4HNE-P+2207, *P*=0.004.](gr1){#f0005}

![Relationship between circulating levels of linoleic acid and cholesterol fractions in the entire population. (A) Correlation between levels of linoleic acid (LA) and total cholesterol, LDL- and LDL-cholesterol in the entire population. The dotted lines show the regression lines: (i) total cholesterol: *R*^2^=0.595, *P*\<0.0001, total cholesterol=0.79×LA+1.52; (ii) LDL-cholesterol: *R*^2^=0.455, *P*\<0.0001, LDL-cholesterol=0.567×LA+0.583; and (iii) HDL: *R*^2^=0.076, *P*=0.001, HDL-cholesterol=0.120×LA+0.726. (B) Circulating levels of LA adjusted for age, gender and lipoproteins variables assessed by ANCOVA. Values are means±SD.](gr2){#f0010}

![Relationship between 4HNE-P and HDL-cholesterol expressed in absolute values or relative to HDL-cholesterol in heart failure (HF) and control (C) subjects. The lines in Fig. 2A show the linear regression lines for each group: (i) HF: *R*^*2*^=0.086, *P*=0.016, regression equation: HDL-cholesterol=0.0014×4HNE-P+0.651, and (ii) controls: *R*^*2*^=0.0149, *P*=0.768, regression equation: HDL-cholesterol=−0.00022×4HNE-P+1.51.](gr3){#f0015}

###### 

Clinical characteristics of heart failure (HF) patients and controls.

  **Parameters**                                                **Control**   **HF**
  ------------------------------------------------------------- ------------- ------------------------------------------------------
  *N*                                                           71            61
  ***Subjects characteristics***                                              
  Gender (male, %)                                              37 (52%)      47 (77%)[⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Age (years)                                                   59±9          67±10[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Body mass index (kg/m^2^)                                     25.9±2.9      26.9±4.3
                                                                              
  ***Clinical parameters***                                                   
  Left ventricular ejection fraction (%)                        n.d.          26.3±7.1
  NYHA Class[a](#tbl1fna){ref-type="table-fn"}                                
   I                                                            n.a.          1 (2%)
   II                                                                         33 (54%)
   III                                                                        27 (44%)
  Systolic blood pressure (mmHg)                                119±13        106±19[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Diastolic blood pressure (mmHg)                               73±8          58±9[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Heart rate (bpm)                                              68±7          68±10
                                                                              
  ***Medical history*****(*****etiology/comorbidities*****)**                 
  Ischemic etiology                                             0             39 (64%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Dyslipidemia                                                  19 (27%)      55 (90%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Hypertension                                                  0             30 (49%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Type 2 diabetes                                               0             29 (48%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  History of myocardial infarction                              0             33 (54%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
                                                                              
  ***Medications***                                                           
  RAS inhibitor                                                 7 (10%)       52 (85%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  β-blocker                                                     3 (4%)        48 (79%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Digoxin                                                       0             42 (69%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Lipid-lowering agents[b](#tbl1fnb){ref-type="table-fn"}       17 (24%)      46 (75%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Diuretics[c](#tbl1fnc){ref-type="table-fn"}                   5 (7%)        59 (97%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Aspirin                                                       1 (1%)        29 (48%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Salicylates                                                   9 (13%)       39 (65%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Chronic nitrate                                               0             18 (30%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Spironolactone                                                0             42 (62%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Acute nitrate                                                 0             22 (36%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Allopurinol                                                   1 (1%)        19 (31%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Amiodarone                                                    0             17 (28%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Warfarin                                                      1 (1%)        29 (48%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}
  Calcium channel antagonists                                   3 (4%)        3 (5%)
  Hypoglycemic agents                                           0             21 (35%)[⁎⁎⁎⁎](#tbl1fnstarstar){ref-type="table-fn"}

Data are means±SD, median \[min−max\] or number of patients (percentage). NYHA, New York Heart Association, n.a., not applicable, n.d., not determined, RAS, renin-angiotensin system.

This classification applies for HF patients only.

Lipid-lowering agents include statins and fibrates.

Diuretics include loop diuretic, thiazides and potassium sparing diuretic.

*P*\<0.05, ^⁎⁎^*P*\<0.01, ^⁎⁎⁎^*P*\<0.001 and ^⁎⁎⁎⁎^*P*\<0.0001: HF vs. controls, using ANCOVA adjusting for age and sex as covariates.

###### 

Standard laboratory parameters assessed in HF patients and controls.

  **Parameters**                                                 **Control**   **HF**
  -------------------------------------------------------------- ------------- ---------------------------------------------------
  NT-Pro-BNP (ng/L)[a](#tbl2fna){ref-type="table-fn"}            57            2641[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
                                                                 \[12--559\]   \[101--35,000\]
  Increased troponin T (≥0.03 µg/L)                              0             11 (16%)
  Creatinine (μM)                                                83±18         160±119[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  eGFR (ml/min)                                                  83.1±21.0     51.7±28[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Blood urea (mM)                                                6.0±1.4       12.1±5.7[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Uric acid (μM)                                                 282±77        431±139[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Total bilirubin (μM)                                           10.6 ±4.9     11.9±7.3
  C-reactive protein (μg/ml)[a](#tbl2fna){ref-type="table-fn"}   2.02±3.22     7.08±9.27[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Tumor necrosis factor-α (pg/ml)                                1.13±0.36     2.26±0.85[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Myeloperoxidase (ng/ml)[a](#tbl2fna){ref-type="table-fn"}      16.9±6.7      28.8±44.0[⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Leukocytes (×10^9^/L)                                          5.80±1.34     7.65±1.98[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Lymphocytes (×10^9^/L)                                         0.30±0.08     0.22±0.07[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Hemoglobin (g/L)                                               142±10        133±16[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Platelets (×10^9^/L)                                           240±52        213±67
  Total cholesterol (mM)                                         5.10±0.79     4.07±1.09[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  HDL-Cholesterol (mM)                                           1.45±0.43     0.90±0.27[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  LDL-Cholesterol (mM)                                           3.15±0.69     2.42±0.92[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Total cholesterol/HDL ratio                                    3.73±0.93     4.74±1.38[⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Triglycerides (mM)                                             1.11±0.53     1.68±1.06[⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Glucose (mM)                                                   4.60±0.47     7.12±2.51[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  Insulin (mU/L)                                                 6.33±2.86     9.85±5.97[⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}
  HOMA-IR                                                        26.7±11.9     55.7±35.1[⁎⁎⁎⁎](#tbl2fnstar){ref-type="table-fn"}

Data are means±SD, median \[min−max\] or number of patients (percentage). NT-ProBNP, N-terminal proB-type natriuretic peptide, eGFR, estimated glomerular filtration rate, HOMA-IR: homeostatic model assessment of insulin resistance, calculated from Ref. [@bib41].

Parameters exhibiting a severely skewed distribution and for which a logarithmic transformation was used.

*P*\<0.05, ^⁎⁎^*P*\<0.01, ^⁎⁎⁎^*P*\<0.001 and ^⁎⁎⁎⁎^*P*\<0.0001: HF vs. controls, using ANCOVA adjusting for age and sex as covariates.

###### 

Circulating levels of oxidative stress-related parameters in HF patients and controls.

  Parameters             **Control**   **HF**
  ---------------------- ------------- -----------------------------------------------------
  GSH (μM)               561.9±154.9   555.6±168.4
  GSSG (μM)              42.9±21.9     33.3±22.2
  GSH-to-GSSG ratio      15.7±7.7      24.3±18.7[⁎⁎](#tbl3fnstarstar){ref-type="table-fn"}
  Malondialdehyde (μM)   967±313       1143±473
  4HNE-P (μM)            223±97        213±113

Data are means±SD. GSH: reduced glutathione; GSSG: oxidized glutathione.

*P*\<0.01: HF vs. controls, using ANCOVA adjusting for age and sex as covariates.

###### 

Total plasma fatty acid concentration in HF patients and controls.

  **Fatty acids/Concentration**                         **Control**               **HF**
  ----------------------------------------------------- ------------------------- ---------------------------------------------------------
  ***TOTAL***                                           ***15,169***±***2951***   ***15,030***±***5433***
  **(*****A*****)*****PUFA***                           ***6202±1012***           ***5298±1526***[⁎⁎⁎⁎](#tbl4fnstar){ref-type="table-fn"}
  ***n-6***                                             ***5518±926***            ***4826±1377***[⁎⁎⁎](#tbl4fnstar){ref-type="table-fn"}
  C18:2n-6 (linoleic acid)                              4226±804                  3592±1192[⁎⁎](#tbl4fnstar){ref-type="table-fn"}
  C18:3n-6 (gamma linolenic)                            70.6±28.1                 69.9±36.3
  C20:3n-6 (dihomogamma acid)                           203±61                    183±67
  C20:4n-6 (arachidonic acid)                           976.2±235.8               930.2±267.0
  ***n-3***                                             ***664±238***             ***446±194***[⁎⁎⁎⁎](#tbl4fnstar){ref-type="table-fn"}
  C18:3n-3 (α-linolenic acid)                           96.3±32.4                 97.0±45.6
  C20:5n-3 (EPA)                                        158±112                   81.4±45.2[⁎⁎⁎⁎](#tbl4fnstar){ref-type="table-fn"}
  C22:5n-3 (DPA)                                        67.4±18.2                 61.2±28.2
  C22:6n-3 (DHA)                                        338±123                   202±109[⁎⁎⁎⁎](#tbl4fnstar){ref-type="table-fn"}
  **(*****B*****)*****Mono-unsaturated fatty acids***   ***3808±1039***           ***4513±2006***[⁎](#tbl4fnstar){ref-type="table-fn"}
  ***n-9***                                             ***3169±821***            ***3788±1587***[⁎⁎](#tbl4fnstar){ref-type="table-fn"}
  C18:1n-9 (oleic acid)                                 2924±808                  3556±1566[⁎](#tbl4fnstar){ref-type="table-fn"}
  C18:1n-9T (elaidic acid)                              33.9±16.5                 45.6±24.5[⁎](#tbl4fnstar){ref-type="table-fn"}
  C20:3n-9 (eicosatrienoic acid)                        19.7±10.1                 26.1±14.8[⁎](#tbl4fnstar){ref-type="table-fn"}
  C22:1n-9 (erucic acid)                                51.7±10.0                 53.6±17.1
  C24:1n-9 (nervonic acid)                              149±38                    126±36[⁎](#tbl4fnstar){ref-type="table-fn"}
  ***n-7***                                             ***604±241***             ***680±431***
  C16:1n-7 (palmitoleic acid)                           361±185                   399±336
  C18:1n-7 (vaccenic acid)                              243±63                    281±108
  ***Trans fatty acids***                               ***50.3±19.9***           ***64.4±29.2***[⁎⁎](#tbl4fnstar){ref-type="table-fn"}
  ***Saturated fatty acids***                           ***5214±1261***           ***5291±2240***
  C12:0 (lauric acid)                                   19.8±10.3                 26.0±21.5
  C14:0 (myristic acid)                                 197±95                    195±123
  C16:0 (palmitic acid)                                 3809±973                  3932±1867
  C18:0 (stearic acid)                                  890±208                   894±249
  C20:0 (arachidic acid)                                30.0±5.4                  27.2±5.3[⁎](#tbl4fnstar){ref-type="table-fn"}
  C22:0 (behenic acid)                                  90.1±19.8                 67.2±22.4[⁎⁎⁎⁎](#tbl4fnstar){ref-type="table-fn"}
  C24:0 (lignoceric acid)                               67.7±21.9                 37.9±15.8[⁎⁎⁎⁎](#tbl4fnstar){ref-type="table-fn"}

Data are means±SD. PUFA, polyunsaturated fatty acid, EPA, eicosapentaenoic acid, DPA, Docosapentaenoic acid, DHA, docosahexanaenoic acid.

*P*\<0.05, ^⁎⁎^*P*\<0.01, ^⁎⁎⁎^*P*\<0.001 and ^⁎⁎⁎⁎^*P*\<0.0001: HF vs. controls, using ANCOVA adjusting for age and sex as covariates.

###### 

Blood level of 4-hydroxynonenal-protein thioether adducts (4HNE-P) and its association with that of its potential precursors in the entire population of HF patients and control subjects.

                     **HF+Control**                        **HF**                                **Control**
  ------------------ ------------------------------------- ------------------------------------- -----------------------
  Total *n-6* PUFA   ***R*****=0.262;*****P*****=0.003**   ***R*****=0.396;*****P*****=0.002**   *R*=0,093; *P*=0.483
  Linoleic acid      ***R*****=0.252;*****P*****=0.004**   ***R*****=0.366;*****P*****=0.004**   *R*=0.106; *P*=0.378
  Arachidonic acid   *R*=0.119; *P*=0.176                  ***R*****=0.316;*****P*****=0.013**   *R*=−0.058; *P*=0.627
  HDL-cholesterol    *R*=0.121; *P*=0.166                  ***R*****=0.323;*****P*****=0.011**   *R*=−0.014; *P*=0.909
  LDL-cholesterol    *R*=0.087; *P*=0.329                  *R*=0.222; *P*=0.085                  *R*=−0.112; *P*=0.358
  Triglycerides      *R*=0.099; *P*=0.254                  *R*=0.128; *P*=0.324                  *R*=0.162; *P*=0.177

Results are Pearson coefficient (*R*) and *P* values from correlation analysis between 4HNE-P and its potential precursors reported in [Tables 2 and 4](#t0010 t0020){ref-type="table"}. Correlations that are significant are shown in bold.

###### 

Parameters associated with blood 4HNE-P and MDA levels in HF patients (**multiple regression analysis**).

  **Parameters**                             **β Coefficient**   ***P***
  ------------------------------------------ ------------------- ---------
  ***4HNE-P (R***^***2***^***=0.5692)***                         
  ***Lipid profile-potential precursors***                       
  Linoleic acid                              0.0184              0.0031
  HDL-Cholesterol                            102.4               0.0002
  ***Disease-related parameters***                               
  NYHA                                       43.4                0.0015
  History of myocardial infarction           35.5                0.0122
  ***Various factors***                                          
  Body mass index                            4.11                0.0194
  Total bilirubin                            −2,06               0.0268
  Ratio GSH/GSSG                             −0.758              0.0462
  ***Medication***                                               
  RAS inhibitors                             63.8                0.0034
  Acute nitrate                              −31.7               0.0034
  Hypoglycemic agents                        −29.1               0.0485
                                                                 
  ***MDA (R***^***2***^***=0.4074)***                            
  ***Disease-related parameters***                               
  History of myocardial infarction           −244                0.0228
  ***Risk factors***                                             
  Hypertension                               233                 0.0286
  ***Biochemical parameters***                                   
  Glucose                                    48.2                0.0202
  Alkaline phosphatase                       2.57                0.0379
  Myeloperoxidase                            4.36                0.0005
  ***Medication***                                               
  Amiodarone                                 −299                0.0151

Multivariate analysis was performed in HF patients only using risk factors and parameters selected for their high clinical and biochemical relevance, which are listed in the Material and Methods. A *P*-value\<0.05 was considered statistically significant.
